MedTrace Logo

A Non-interventional Study of Participants With BPDCN Treated With Chemotherapy

NCT07785180 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 140

Last updated 2026-08-25

No results posted yet for this study

Summary

The main goal of this study is to investigate the effectiveness and safety of chemotherapy agents in the treatment of participants with BPDCN and to provide comparator arm data to the prospective ELZONRIS registry study (STML-401-0521).

Conditions

  • Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Interventions

DRUG

Chemotherapy

Several chemotherapy regimens can be considered (acute myeloid leukemia-like, acute lymphocytic leukemia-like, lymphoma-like). The choice of the regimen, as well as dosing and schedules, are based on the institution's and the health care provider's preferences. No study medication will be provided by the sponsor during this study.

Sponsors & Collaborators

  • Stemline Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Medical Director · Stemline Therapeutics, Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-17
Primary Completion
2027-05-31
Completion
2027-12-31

Countries

  • Denmark
  • France
  • Germany
  • Greece
  • Italy
  • Netherlands
  • Poland
  • Portugal
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07785180 on ClinicalTrials.gov